{"id":349,"date":"2020-09-23T03:02:19","date_gmt":"2020-09-23T03:02:19","guid":{"rendered":"http:\/\/www.cd-bioparticles.net\/blog\/?p=349"},"modified":"2023-07-25T09:58:48","modified_gmt":"2023-07-25T09:58:48","slug":"cardiovascular-drug-liposome","status":"publish","type":"post","link":"https:\/\/www.cd-bioparticles.net\/blog\/cardiovascular-drug-liposome\/","title":{"rendered":"Cardiovascular Drug Liposome"},"content":{"rendered":"

Cardiovascular disease, also known as circulatory system disease, is a disease with high human mortality.\u00a0Approximately 17 million people die from cardiovascular disease worldwide each year.\u00a0Cardiovascular and cerebrovascular diseases mostly occur after the age of 40.\u00a0There are more men than women, and more mental workers than manual workers.\u00a0The average prevalence is about 6.49%, and the prevalence increases with age.\u00a0Affected by the high-fat, fast-paced, and high-stress lifestyle, the prevalence of cardiovascular and cerebrovascular diseases is increasing year by year, and the age of illness tends to be younger.\u00a0Cardiovascular disease has become a major global medical problem.
\nAccording to the mechanism of action, drugs for the treatment of cardiovascular diseases can be divided into angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARB), \u03b2-blockers, nitrates, diuretics, \u03b1- blockers, cardiotonic drugs and digitalis, lipid regulating drugs, antiarrhythmic drugs, calcium channel blockers, myocardial nutrition drugs;\u00a0according to the disease can be divided into lowering blood pressure drugs, coronary heart disease drugs, and cardiac insufficiency drugs , Anticoagulant and antithrombotic drugs.\u00a0Drug therapy is currently the most important and preferred method for the treatment of cardiovascular diseases, but most of the drugs lack tissue specificity and lesion site targeting. The amount of drugs is large, and some can cause toxic side effects. Therefore, the efficacy of drugs is not significant, and new types of drugs are urgently needed.<\/p>\n

\"\"
Figure 1. The Diagram of an arterial section showing possible interaction with vascular target antigens attached to nanocarriers that are loaded with therapeutic or site-specific diagnostic ligands.<\/figcaption><\/figure>\n

New Cardiovascular Drug Liposome<\/b><\/strong>
\n<\/b><\/strong>Thrombus <\/b><\/strong>Targeting Liposome<\/b><\/strong>
\nCardiovascular disease is large-partly caused by blood clots.\u00a0Thrombolytic drugs such as urokinase are used in large amounts, lack targeting and have a short action time.\u00a0Targeted therapy is necessary for thrombotic diseases.\u00a0Prostaglandin Er liposomes<\/u><\/a>\u00a0(Lipo-PGE) can significantly inhibit ADP-induced thrombosis and subsequent microcirculation vascular damage.\u00a0Compared with ordinary prostaglandin E (PCE) preparations, the effect is significantly enhanced.\u00a0The reperfusion time Lipo-PGEi group is PGE 1\/4.\u00a0In addition, using Lipo-PGEi after thrombosis is more effective than using Lipo-PGEi before thrombosis, indicating that liposomes can effectively target drugs to thrombus.\u00a0Synthesize the specific ligand H-Arg-Gly-Asp-SeOH (RGDs) targeting thrombus, which is coupled with Distearoyl-phosphatidylethanolamine-polyethylene glycol 3500-carboxyl group and inserted into the liposome bilayer membrane, and then the thrombus-targeted urokinase liposome was obtained.\u00a0The thrombolytic effect in vivo was investigated on the rat common carotid artery thrombosis model.\u00a0The weight of thrombus in the free urokinase group was almost unchanged;\u00a0the weight of the thrombus in the liposome urokinase group was slightly reduced but there was no significant difference.\u00a0The weight of the thrombus in the thrombus-targeted urokinase liposome group was significantly reduced, and the dosage was reduced to 1\/5, indicating Blood-targeted urine microenzyme liposome has obvious targeted thrombolytic effect.<\/p>\n

Myocardial <\/b><\/strong>Targeting Liposome<\/b><\/strong>
\nThree factors should be considered for cardio-cerebrovascular targeting liposomes: \u2460Find specific receptors on the cardio-cerebrovascular;\u00a0\u2461Attach ligands that specifically bind to the receptors on the surface of the liposomes, \u2462prevent the liposomes from being meshed The endothelial system is removed.\u00a0The \u03b2 receptor ligand allylolol is mixed into human liposome membrane to make myocardial targeted liposomes, which are mainly distributed in tissues and organs rich in \u03b2 receptors such as heart and lung.\u00a0The liposome can treat myocardial necrosis after encapsulating reduced glutathione and reduce the dosage of drugs.\u00a0Myocardial ischemia can lead to the death of cardiomyocytes, and antibodies against intracellular antigens can distinguish live cells from dead cells, undamaged cell membranes and damaged cell membranes.\u00a0Myosin in the heart will not be taken away due to cell rupture and can be used as a target for antigen-specific binding during myocardial ischemia.\u00a0For example, liposomes modified with anti-myosin antibodies can actively target the ischemic myocardium Location.\u00a0The interaction mechanism between cardiomyocytes and liposomes is not very clear.\u00a0Cardiomyocytes may adsorb liposomes and interact with liposomes through membrane lipid exchange, fusion, and endocytosis.\u00a0The liposomes deliver drugs into the cardiomyocytes.\u00a0Experiments have proved that the isolated rat cardiomyocytes take up liposomes in a variety of ways, and the mode of action mainly depends on the physical state of the liposomes (phase transition temperature and electrical properties), rather than the lipid composition.\u00a0For positively charged The uptake of liposomes is much greater than that of negatively charged liposomes.\u00a0The gel state liposomes ingested through endocytosis and adsorption are higher than the liquid crystal state liposomes, and the liquid crystal neutral liposomes ingested are higher than the liquid crystal state charged liposomes.\u00a0The uptake of liposomes, especially positively charged liposomes, by ischemic myocardium tissue increases significantly.\u00a0The order of intake is: ischemia-reperfusion zone, infarct marginal zone, non-ischemic zone and infarct zone.\u00a0The mechanism It is related to K and Ca disorders in damaged tissues and membrane lipid peroxidation.\u00a0Therefore, liposomes are an ideal carrier and are used to carry drugs.\u00a0Further animal model analysis found,\u00a0liposomes were significantly increased in the heart and lungs of rats with isoprenaline myocardial ischemia, and\u00a0the uptake of liposomes in the duodenum, jejunum, ileum, and heart of rats with superior mesenteric artery occlusion shock increased significantly.\u00a0In addition, liposomes are more distributed in the liver and lungs, and these organs themselves are the main target organs of shock.\u00a0What is more significant is that the uptake of liposomes by the small intestine tissue after ischemia doubles, so liposomes are used as drug carriers for treatment of myocardial ischemia and anti-shock has good prospects.<\/p>\n","protected":false},"excerpt":{"rendered":"

Cardiovascular disease, also known as circulatory system disease, is a disease with high human mortality.\u00a0Approximately 17 million people die from cardiovascular disease worldwide each year.\u00a0Cardiovascular and cerebrovascular diseases mostly occur after the age of 40.\u00a0There are more men than women, and more mental workers than manual workers.\u00a0The average prevalence is about 6.49%, and the prevalence increases with age.\u00a0Affected by the high-fat, fast-paced, and high-stress lifestyle, the prevalence of cardiovascular and cerebrovascular diseases is increasing year by year, and the age of illness tends to be younger.\u00a0Cardiovascular disease has become a major global medical problem. According to the mechanism of action, drugs for the treatment of cardiovascular diseases can be divided into angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARB), \u03b2-blockers, nitrates, diuretics, \u03b1- blockers, cardiotonic drugs and digitalis, lipid regulating drugs, antiarrhythmic drugs, calcium channel blockers, myocardial nutrition drugs;\u00a0according to the disease can be divided into lowering blood pressure drugs, coronary heart disease drugs, and cardiac insufficiency drugs , Anticoagulant and antithrombotic drugs.\u00a0Drug therapy is currently the most important and preferred method for the treatment of cardiovascular diseases, but most of the drugs lack tissue specificity and lesion site targeting. The amount of drugs is large, and some can cause toxic side effects. Therefore, the efficacy of drugs is not significant, and new types of drugs are urgently needed. New Cardiovascular Drug Liposome Thrombus Targeting Liposome Cardiovascular disease is large-partly caused by blood clots.\u00a0Thrombolytic drugs such as urokinase are used in large amounts, lack targeting and have a short action time.\u00a0Targeted therapy is necessary for thrombotic diseases.\u00a0Prostaglandin Er liposomes\u00a0(Lipo-PGE) can significantly inhibit ADP-induced thrombosis and subsequent microcirculation vascular damage.\u00a0Compared with ordinary prostaglandin E (PCE) preparations, the effect is significantly enhanced.\u00a0The reperfusion time Lipo-PGEi group is PGE 1\/4.\u00a0In addition, using Lipo-PGEi after thrombosis is more effective than using Lipo-PGEi before thrombosis, indicating that liposomes can effectively target drugs to thrombus.\u00a0Synthesize the specific ligand H-Arg-Gly-Asp-SeOH (RGDs) targeting thrombus, which is coupled with Distearoyl-phosphatidylethanolamine-polyethylene glycol 3500-carboxyl group and inserted into the liposome bilayer membrane, and then the thrombus-targeted urokinase liposome was obtained.\u00a0The thrombolytic effect in vivo was investigated on the rat common carotid artery thrombosis model.\u00a0The weight of thrombus in the free urokinase group was almost unchanged;\u00a0the weight of the thrombus in the liposome urokinase group was slightly reduced but there was no significant difference.\u00a0The weight of the thrombus in the thrombus-targeted urokinase liposome group was significantly reduced, and the dosage was reduced to 1\/5, indicating Blood-targeted urine microenzyme liposome has obvious targeted thrombolytic effect. Myocardial Targeting Liposome Three factors should be considered for cardio-cerebrovascular targeting liposomes: \u2460Find specific receptors on the cardio-cerebrovascular;\u00a0\u2461Attach ligands that specifically bind to the receptors on the surface of the liposomes, \u2462prevent the liposomes from being meshed The endothelial system is removed.\u00a0The \u03b2 receptor ligand allylolol is mixed into human liposome membrane to make myocardial targeted liposomes, which are mainly distributed in tissues and organs rich in \u03b2 receptors such as heart and lung.\u00a0The liposome can treat myocardial necrosis after encapsulating reduced glutathione and reduce the dosage of drugs.\u00a0Myocardial ischemia can lead to the death of cardiomyocytes, and antibodies against intracellular antigens can distinguish live cells from dead cells, undamaged cell membranes and damaged cell membranes.\u00a0Myosin in the heart will not be taken away due to cell rupture and can be used as a target for antigen-specific binding during myocardial ischemia.\u00a0For example, liposomes modified with anti-myosin antibodies can actively target the ischemic myocardium Location.\u00a0The interaction mechanism between cardiomyocytes and liposomes is not very clear.\u00a0Cardiomyocytes may adsorb liposomes and interact with liposomes through membrane lipid exchange, fusion, and endocytosis.\u00a0The liposomes deliver drugs into the cardiomyocytes.\u00a0Experiments have proved that the isolated rat cardiomyocytes take up liposomes in a variety of ways, and the mode of action mainly depends on the physical state of the liposomes (phase transition temperature and electrical properties), rather than the lipid composition.\u00a0For positively charged The uptake of liposomes is much greater than that of negatively charged liposomes.\u00a0The gel state liposomes ingested through endocytosis and adsorption are higher than the liquid crystal state liposomes, and the liquid crystal neutral liposomes ingested are higher than the liquid crystal state charged liposomes.\u00a0The uptake of liposomes, especially positively charged liposomes, by ischemic myocardium tissue increases significantly.\u00a0The order of intake is: ischemia-reperfusion zone, infarct marginal zone, non-ischemic zone and infarct zone.\u00a0The mechanism It is related to K and Ca disorders in damaged tissues and membrane lipid peroxidation.\u00a0Therefore, liposomes are an ideal carrier and are used to carry drugs.\u00a0Further animal model analysis found,\u00a0liposomes were significantly increased in the heart and lungs of rats with isoprenaline myocardial ischemia, and\u00a0the uptake of liposomes in the duodenum, jejunum, ileum, and heart of rats with superior mesenteric artery occlusion shock increased significantly.\u00a0In addition, liposomes are more distributed in the liver and lungs, and these organs themselves are the main target organs of shock.\u00a0What is more significant is that the uptake of liposomes by the small intestine tissue after ischemia doubles, so liposomes are used as drug carriers for treatment of myocardial ischemia and anti-shock has good prospects.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[28],"class_list":["post-349","post","type-post","status-publish","format-standard","hentry","category-liposomes","tag-cardiovascular"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/posts\/349"}],"collection":[{"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/comments?post=349"}],"version-history":[{"count":3,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/posts\/349\/revisions"}],"predecessor-version":[{"id":528,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/posts\/349\/revisions\/528"}],"wp:attachment":[{"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/media?parent=349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/categories?post=349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cd-bioparticles.net\/blog\/wp-json\/wp\/v2\/tags?post=349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}